Smith & Nephew plc (NYSE: SNN) will acquire Healthpoint Biotherapeutics’ assets for $782 million in cash.

Fort Worth, Texas-based Healthpoint focuses on biopharmaceutical products related to burn wound care. Its portfolio of products include Oasis Wound Matrix, Xenaderm Ointment, Prudoxin and Curasol.

Smith & Nephew, headquartered in London, is a medical technology business that offers products for orthopedic reconstruction, trauma, sports medicine and advanced wound management.

 

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.